- Home
- LOMA vs REPL Comparison
LOMA vs REPL Comparison
Compare LOMA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- REPL
- Stock Information
- Founded
- LOMA 1926
- REPL 2015
- Country
- LOMA Argentina
- REPL United States
- Employees
- LOMA N/A
- REPL N/A
- Industry
- LOMA Building Materials
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- LOMA Industrials
- REPL Health Care
- Exchange
- LOMA Nasdaq
- REPL Nasdaq
- Market Cap
- LOMA 819.2M
- REPL 897.3M
- IPO Year
- LOMA 2017
- REPL 2018
- Fundamental
- Price
- LOMA N/A
- REPL $12.50
- Analyst Decision
- LOMA Sell
- REPL Strong Buy
- Analyst Count
- LOMA 2
- REPL 6
- Target Price
- LOMA $6.55
- REPL $17.50
- AVG Volume (30 Days)
- LOMA 901.4K
- REPL 1.0M
- Earning Date
- LOMA 11-06-2024
- REPL 02-06-2025
- Dividend Yield
- LOMA 1.22%
- REPL N/A
- EPS Growth
- LOMA N/A
- REPL N/A
- EPS
- LOMA 0.63
- REPL N/A
- Revenue
- LOMA $265,542,171.00
- REPL N/A
- Revenue This Year
- LOMA N/A
- REPL N/A
- Revenue Next Year
- LOMA N/A
- REPL $300.41
- P/E Ratio
- LOMA $18.70
- REPL N/A
- Revenue Growth
- LOMA N/A
- REPL N/A
- 52 Week Low
- LOMA $5.70
- REPL $4.92
- 52 Week High
- LOMA $13.79
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- LOMA 52.52
- REPL 49.11
- Support Level
- LOMA $11.88
- REPL $11.19
- Resistance Level
- LOMA $13.79
- REPL $13.04
- Average True Range (ATR)
- LOMA 0.66
- REPL 0.69
- MACD
- LOMA -0.21
- REPL -0.09
- Stochastic Oscillator
- LOMA 18.56
- REPL 52.51
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue Derives from Cement, masonry cement, and lime segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.